A novel Liver & Brain multi-organ-chip model : rapid and reduced cost pre-clinical safety drug screening

小说《肝脏》

• 批准号: 10035032
• 金额: $ 33.55万
• 依托单位: REVIVOCELL LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10035032
• 关键词: novel; Liver; Brain; multi; organ

Cell culture involves the growth of living cells in laboratory conditions without using animals in order to gain better understanding of body function, disease or to develop new drugs. Conventionally, cells are grown in 2-D glass or plastic surfaces such as Petri-dishes and plates, and are normally cultured in isolation, ignoring multiple cell types important in maintaining tissue function. However, no cell lives alone in the human body and creating multiple cell type tissue models are essential to mimic the true nature of organ specific function and improve research and drug discovery.Researchers across many sectors, including the pharmaceutical industry, research organisations and universities apply conventional cell culture for the growth and testing of mammalian cells. Cell culture has played a vital role in many life science discoveries such as the development of new drugs or vaccines. However, the results often lack relevance when tested in patients as the cell growth is constrained within the available 2-D surface when compared to true three-dimensional (3-D) complex multicellular environments of living tissue.Drug-induced liver injury (DILI) and neurotoxicity are leading causes of drug failure during development and post-market drug withdrawal. There is a need for a more predictive tools to assess liver and neurotoxicity risks early in drug discovery. Human cell-based laboratory models for pre-clinical safety screening are increasingly being developed as alternative methods to animal testing.Revivocell Ltd is developing a novel Organ-on-a-chip (OOAC) cell culture platform, that can better simulate the environment for cells to enhance their function, for example as a liver in an _in-vitro_ setting. Existing 3-D cell culture technologies aiming to promote liver specific functionality are expensive, difficult to use and are not easily adaptable for different experiments and cell types.This technology has the potential to increase the success rate of developing new treatments and reduce the reliance on animal testing. The objective of this project is to assess the feasibility of a newly developed OOAC technology to mimic the liver and neuro-specific microenvironment. Revivocell's invention will provide a reliable, fast and cost effective device that could be used worldwide

细胞培养涉及在实验室条件下生长活细胞，而不使用动物，以便更好地了解身体功能、疾病或开发新药。传统上，细胞是在二维玻璃或塑料表面(如培养皿和培养皿)中培养的，通常是隔离培养的，忽略了多种细胞类型对维持组织功能的重要性。然而，没有细胞单独生活在人体内，建立多细胞类型的组织模型对于模拟器官特定功能的真实本质和促进研究和药物发现至关重要。包括制药行业、研究机构和大学在内的许多部门的研究人员将传统细胞培养应用于哺乳动物细胞的生长和测试。细胞培养在许多生命科学发现中发挥了至关重要的作用，例如新药或疫苗的开发。然而，当在患者身上测试时，结果往往缺乏相关性，因为与活组织的真实三维(3-D)复杂的多细胞环境相比，细胞生长被限制在可用的二维表面内。药物诱导的肝损伤(DILI)和神经毒性是药物开发期间和上市后停药期间药物失败的主要原因。需要一种更具预测性的工具来在药物发现的早期评估肝脏和神经毒性风险。作为动物试验的替代方法，基于人类细胞的临床前安全性筛选实验室模型正在日益发展。Revivocell有限公司正在开发一种新型的单芯片器官(OOAC)细胞培养平台，该平台可以更好地模拟细胞增强其功能的环境，例如，作为体外设置的肝脏。现有的旨在促进肝脏特异性功能的三维细胞培养技术价格昂贵、使用困难，而且不容易适应不同的实验和细胞类型。这项技术有可能提高新疗法的开发成功率，减少对动物试验的依赖。该项目的目的是评估一种新开发的OOAC技术模拟肝脏和神经特异性微环境的可行性。Revivocell的发明将提供一种可靠、快速和具有成本效益的设备，可以在全球范围内使用